Drug Development Pipeline
Inhaled Nitric Oxide
Nitric oxide is a gas with antimicrobial properties that may reduce lung infections when inhaled, leading to improved lung function in people with CF.
A phase 2 study to test the safety and effectiveness of inhaled nitric oxide in adults with CF is underway.
This program is sponsored by Novoteris and partially funded by the Cystic Fibrosis Foundation. It is being conducted within the Therapeutics Development Network.
Recent Inhaled Nitric Oxide Studies
Closed to Enrollment
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More